PAG
TVRD

Private Advisor Group’s Tvardi Therapeutics TVRD Stock Holding History

Private Advisor Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-49
Closed -$30K – 3512
2020
Q2 		$30K Buy
+49
New +$27.1K ﹤0.01% 2362
2017
Q2 		– Sell
-659
Closed -$417K – 1478
2017
Q1 		$417K Buy
659
+360
+120% +$192K 0.01% 917
2016
Q4 		$117K Buy
+299
New +$96K ﹤0.01% 1210

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Advisor Group's TVRD Position: Q3 2020 in Review

Private Advisor Group sold out of Tvardi Therapeutics (TVRD) in Q3 2020, closing a stake of 49 shares — an estimated $30K sold.

Private Advisor Group first reported a position in TVRD in Q4 2016 and held it in 3 quarters. The position peaked at $417K in Q1 2017. 161 funds tracked by Wall St. Rank hold TVRD as of Q3 2020.

  • Private Advisor Group reported no remaining Tvardi Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 49 Tvardi Therapeutics shares in Q3 2020, an estimated $30K.
  • Private Advisor Group first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 3 quarters.
  • Private Advisor Group's Tvardi Therapeutics position peaked at $417K in Q1 2017.
  • 161 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.